Top Tweets for #CAPItello291
Highlights on #ESMOBreast26 from #CommunityOnc:
Her2
1. #DB11 Update: NeoAdj TDXd
2. #PHERGain: De-escalation
3. #SATEEN: Sacituzumab
HR+
4. #PREcoopERA: Role of OFS
5. #CAPItello291 Update: Capivasertib
TNBC
6. #TROPIONBreast02: DatoDXd
#OncTwitter #bcsm @myESMO
1/7
This episode of our #BreastCancerBreakthroughs series, has Drs. Harold Burstein (@DrHBurstein) and Erica Mayer (@elmayermd) discuss the #CAPItello291, #VIKTORIA1, and #STX478 trials which were presented at #SABCS25. Watch the recording here ⬇️
https://t.co/ihaT8gkqmH
1. #Capivasertib approved on 11/16/23 w/ AKT pathway alteration based off: #CAPItello291. Capi + Fulvestrant vs Fulvestrant + Placebo
- ⬆️ PFS w/ capivasertib 7.2mos vs 3.6mos (HR 0.60)
- Pending OS
- 400mg BID, 4days on/3days off
https://t.co/N26lS6YzAR
#bcsm
2/6
Finally, and only approved a couple of weeks ago, is Capivasertib (Trucap), an AKT inhibitor, approved for those with mutations in the PIK3CA-AKT-MTOR pathway or loss of PTEN. PFS was better in those with these mutations, confirmed by blinded independent review. #SABCS23
#SABCS23 Day 1 Highlights #CommunityOnc:
@FDAOncology Review on recent approvals
1. #CAPItello291
2. #EMERALD
3. #TDxD
4. Tumor Agnostic landscape
5. Post CDK4/6i HR+
@SABCSSanAntonio @VivekSubbiah @VKaklamani @JaniceTNBCmets #bcsm @DrSGraff @oreganruth
1/6
بالامس وافقت #USFDA على الدواء Capivasertib لمرضى سرطان الثدي الهرموني المنتشر بالجسم Metastatic Breast Cancer Hormone Positive
جاءت الموافقه بعد النتائج لدراسه #CAPItello291 تم فيها مقارنه استخدام الدواء بالاضافه الى دواء ال fulvestrant لبحث استدامه مقاومه تطور المرض PFS
#Capivasertib now @FDAOncology approved w/ AKT alteration based off: #CAPItello291: Capi + Fulvestrant vs Fulvestrant + Placebo
- ⬆️ PFS w/ capivasertib 7.2mos vs 3.6mos (HR 0.60)
- Pending OS
- 400mg BID, 4days on/3days off
- Diarrhea a big SE
#bcsm #MedTwitter #OncTwitter
Pre-ASCO treat: #CAPItello291 is now out on NEJM! Meaningful improvement in PFS with capivasertib added to fulvestrant, particularly in Akt-path altered tumors (40%); benefit less clear in non-altered tumors. Tox: diarrhea (72%), rash (38%) & nausea (34%). https://t.co/kHqkTZBn8u
🎥 @matteolambe explains that we have more data from #ESMOBreast23 on the role of neoadjuvent therapies, that is the most promising way to implement immunotheraphy in early #Breastcancer.
Watch: 👉https://t.co/UKnbe6apea👈
@UniGenova @SanMartino_Ge @myESMO #CAPItello291 #DESTINYBreast04 #IMpassion031
Nick Turner presents subgroup analyses from #CAPItello291. Interesting to look at outcomes in pts pretreated with CDK4/6-inhibitors: significant benefit of adding capi to fulvestrant, but smaller absolute numbers (5.5 vs 2.6 months) vs ITT. Numbers quite similar to #MAINTAIN.
Further convincing efficacy data from the #CAPItello291 trial presented at #ESMObreast23: consistent PFS benefit across all subgroups of patients with endocrine resistant #BreastCancer receiving #capivasertib added to #fulvestrant
@myESMO @OncoAlert @ErikaHamilton9 #bcsm
#ESMOBreast23 Nick Turner presents subgroup analyses from #Capitello291
Benefit from adding #capivasertib irrespective of prior CDK46i or chemotherapy for advanced disease.
Intruiging that lower PFS for fulvestrant was observed after CDK46i
@OncoAlert @myESMO
1. #SABCS22 updates w/ @DrSGraff from @BrownUCancer on HR+ #breastcancer:
- #TAM01 "BabyTam"
- #EMERALD: Elacestrant
- #CAPItello291: Capivasertib
- #TROPiCS2: Sacituzumab Govitecan
https://t.co/c3OFI7jb6N
#bcsm #SABCSUpdate
@OncoAlert @SoMeCME @SABCSSanAntonio
1/ #SABCSUpdate
📣 #OncTwitter: Clinically relevant updates on CDK4/6 inhibitors in HR+/HER2- advanced #breastcancer w/ @DrSGraff & @OncBrothers!
Supported by educational grants from Gilead & Lilly.
CME ℹ️ https://t.co/AxyPrqAEIi
📊 What is your specialty❓
The #OncoAlertTopTweet 🚨Day3⃣ #SABCS22
Tweet @ErikaHamilton9 🇺🇸
#CAPItello291 fulvestrant +/- capivasertib (AKT) 4 d on, 3 d off
✅PFS fulv 3.6 mo vs. 7.2 mo w/ capo a, HR 0.60
🔹Benefit still there among pts without alterations‼️
🔸OS immature]
Best,
@weoncologists
#CAPItello291 fulvestrant +/- capivasertib (AKT) 4 d on, 3 d off
✅PFS fulv 3.6 mo vs. 7.2 mo w/ capo a, HR 0.60
🔹Benefit still there among pts without alterations‼️
🔸OS immature
~70% w/ 💩, 9% G3
38% rash, 5% G3
#SABCS22 @OncoAlert #bcsm
1. #CAPItello291: Capivasertib + Fulvestrant vs Fulvestrant + Placebo
- improved PFS with capivasertib 7.2mos vs 3.6mos (HR 0.60)
- Benefit seen with and without AKT alterations
- Pending OS
- Lots of diarrhea
2/5
Day 3 #SABCS2022 Highlights #CommunityOncology
1. #CAPItello291: #Capivasertib
2. #EMERALD: #Elacestrant
3. #PACE: Palbo/Avelumab/SERD
4. #OralContraceptives in mBRCA
#bcsm #MedTwitter @SoMeCME
#OncEd #SABCSUpdates @HemOncFellows @SABCSSanAntonio #breastcancer
1/5
Great results from #CAPItello291 trial just presented at #SABCS22 showing improved outcomes with the addition of #capivasertib to fulvestrant in pretreated patients with advanced HR+/HER2- #BreastCancer
@SABCSSanAntonio @OncoAlert #bcsm
#CAPItello291 showed that FUL + #capivasertib (AKTi)
~2x PFS 📈 (HR 0.60) in ITT
>2x PFS 📈 (HR 0.50) in AKT altered pathway
Trend toward 📈 OS
Prior CDK use ~70%
No prior SERD
👉🏻13% discon.; 72% diarrhea (G1)
#SABCS22 #EndCancer @OncoAlert
👏🏼@AstraZeneca
#CAPItello291 fulvestrant +/- capivasertib (AKT) 4 d on, 3 d off
✅PFS fulv 3.6 mo vs. 7.2 mo w/ capo a, HR 0.60
🔹Benefit still there among pts without alterations‼️
🔸OS immature
~70% w/ 💩, 9% G3
38% rash, 5% G3
#SABCS22 @OncoAlert #bcsm
Komal Jhaveri (@jhaveri_komal) reviews the data of agents targeting the PI3K/Akt/mTOR pathway, highlighting the encouraging phase 2 data of capivasertib & the announcement of the positive phase 3 data from #CAPItello291. Breast cancer research is running fast! #PBCClive22 #bcsm
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.4M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.9M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.5M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.8M followers
KATY PERRY
@katyperry
87.3M followers
Taylor Swift
@taylorswift13
81.1M followers
Lady Gaga
@ladygaga
72.7M followers
Kim Kardashian
@kimkardashian
69.6M followers
Virat Kohli
@imvkohli
69.3M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.7M followers
The Ellen Show
@theellenshow
62.5M followers
Neymar Jr
@neymarjr
62M followers
CNN
@cnn
61.9M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.4M followers